Current concepts of the diagnosis of adult growth hormone deficiency
- PMID: 32959175
- DOI: 10.1007/s11154-020-09594-1
Current concepts of the diagnosis of adult growth hormone deficiency
Abstract
In adults, growth hormone (GH) deficiency is associated with increased visceral adiposity, decreased lean body mass, bone mineral density and exercise capacity, dyslipidemia, insulin resistance, increased cardiometabolic and fracture risk, and impaired quality of life. The aim of the present article is to review the diagnosis of GH deficiency in adults. To avoid overdiagnosis of GH deficiency, it is critical to evaluate only patients at risk for pituitary dysfunction, including those who have had sellar masses, pituitary surgery, radiation therapy, traumatic brain injury, subarachnoid hemorrhage or childhood onset GH deficiency. Evaluation for GH deficiency should be undertaken after testing and replacement of other pituitary hormone deficits. Since GH secretion is pulsatile, measuring serum GH levels randomly is not helpful in establishing the diagnosis of GH deficiency. Serum insulin-like growth factor I (IGF-I) levels lack substantial diurnal variation but also lack sufficient sensitivity and specificity in the diagnosis of GH deficiency in adults. However, adults with multiple (≥3) additional pituitary hormone deficiencies, risk factors for hypopituitarism and low serum IGF-I levels are very likely to be GH deficient. In most cases, the diagnosis of GH deficiency requires stimulation testing. These tests involve the administration of a pharmacologic agent that normally stimulates GH release from pituitary somatotrophs, including insulin, glucagon, growth hormone releasing hormone-arginine or macimorelin, followed by sampling of serum specimens at regular intervals for GH assay. Patients with a peak GH level that is below a predetermined cutpoint are classified as GH deficient. A systematic approach to the diagnosis of GH deficiency is essential in order to accurately identify adults who may benefit from GH replacement.
Keywords: Glucagon; Growth hormone deficiency; Growth hormone releasing hormone; Insulin; Insulin-like growth factor I; Macimorelin.
Similar articles
-
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE.Endocr Pract. 2019 Nov;25(11):1191-1232. doi: 10.4158/GL-2019-0405. Endocr Pract. 2019. PMID: 31760824
-
Growth hormone deficiency in adults with Cushing's disease.Best Pract Res Clin Endocrinol Metab. 2021 Mar;35(2):101474. doi: 10.1016/j.beem.2020.101474. Epub 2020 Nov 24. Best Pract Res Clin Endocrinol Metab. 2021. PMID: 33272904 Review.
-
The diagnosis of severe growth hormone deficiency in elderly patients with hypothalamic-pituitary disease.Clin Endocrinol (Oxf). 1998 May;48(5):569-76. doi: 10.1046/j.1365-2265.1998.00440.x. Clin Endocrinol (Oxf). 1998. PMID: 9666868
-
Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency.J Clin Endocrinol Metab. 2002 May;87(5):2067-79. doi: 10.1210/jcem.87.5.8509. J Clin Endocrinol Metab. 2002. PMID: 11994342 Clinical Trial.
-
Diagnosis of growth hormone deficiency in adults.Horm Res. 1996;46(4-5):174-82. doi: 10.1159/000185019. Horm Res. 1996. PMID: 8950617 Review.
Cited by
-
Relationship between plasma urea and copeptin in response to arginine stimulation in healthy adults, patients with vasopressin deficiency and primary polydipsia.Pituitary. 2025 Jan 25;28(1):18. doi: 10.1007/s11102-024-01489-7. Pituitary. 2025. PMID: 39863827 Free PMC article.
-
Investigating significant health trends in growth hormone treatments registry: rationale, aims and design of a nationwide prospective registry (study protocol).Orphanet J Rare Dis. 2023 May 10;18(1):112. doi: 10.1186/s13023-023-02716-3. Orphanet J Rare Dis. 2023. PMID: 37165422 Free PMC article.
-
High-dose glucocorticoid treatment vs. glucocorticoid replacement in immune checkpoint inhibitor associated hypophysitis (CORTICI): an open, randomised controlled trial.Ann Med. 2025 Dec;57(1):2453829. doi: 10.1080/07853890.2025.2453829. Epub 2025 Jan 25. Ann Med. 2025. PMID: 39862267 Free PMC article. Clinical Trial.
-
High-coverage targeted lipidomics revealed a novel serum lipid dysregulation profile in adult growth hormone deficiency.Endocr Connect. 2024 Dec 20;14(1):e240424. doi: 10.1530/EC-24-0424. Print 2025 Jan 1. Endocr Connect. 2024. PMID: 39530793 Free PMC article.
-
Binding Domain Characterization of Growth Hormone Secretagogue Receptor.J Transl Int Med. 2022 Jul 2;10(2):146-155. doi: 10.2478/jtim-2022-0033. eCollection 2022 Jun. J Transl Int Med. 2022. PMID: 35959447 Free PMC article.
References
-
- Ho KK, on behalf of other participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH research society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol. 2007;157:695–700. - PubMed - DOI
-
- Yuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM, et al. American association of clinical endocrinologists and American college of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract. 2019;25:1191–232. - PubMed - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources